doi: 10.3892/ol.2025.15393 105 Bonnefont-RousselotD
Sulofenur [( N -(5-indanesulfonyl)- N -(4-chlorophenyl)urea, LY18664], the prototypic member of this class ( Figure 2C ), was evaluated in clinical trials on a variety of patients with kidney (Mahjoubi et al., 1993), ovary (OBrien et al., 1992), breast (Talbot et al., 1993), lung (Munshi et al., 1993), and stomach (Kamthan et al., 1992) cancers
8 Future directions Conventional antioxidants face limitations in efficacy and specificity, but emerging strategiesincluding mitochondria-targeted compounds and Nrf2 activatorsaddress these challenges through three transformative mechanisms: Precision targeting Unlike broad-acting scavengers, these agents accumulate within mitochondria, the primary source of ROS
Moreover, increased cellular uptake of Zn 2+ through the upregulation of zinc transporter ZIP8 activates metal-regulatory transcription factor-1 (MTF1), which in turn induces the expression of matrix-degrading enzymes in chondrocytes 33,83
Claims examiners expect documentation showing the physicians review, supervision, and interpretation rather than ownership of equipment or staff
